# Biotech Daily Digest — 2025-12-07

**2 items from 2 sources**

## Summary by Source

- Endpoints News: 1 item
- Fierce Biotech: 1 item


## Endpoints News

- **[#ASH25: AstraZeneca's dual-targeting CAR-T sees similar responses in Western patients as in China](https://endpoints.news/astrazenecas-dual-targeting-car-t-sees-similar-responses-in-western-patients-as-in-china/)**  
  _Sat, 06 Dec 2025 20:00:15 +0000_  
  ORLANDO — The first data in Western cancer patients for AstraZeneca's dual-targeting CAR-T cell therapy appear to hold up with impressive, earlier results from China-only studies.

 AstraZeneca presented preliminary results on Saturday at the American Society ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/markets-thinking-backwards-fdas-1-trial-approval-plan-would-boost-rd-spend-jefferies" hreflang="en">'Market's thinking is backwards': FDA's 1-trial approval plan would boost R&amp;D spend, Jefferies says</a>](https://www.fiercebiotech.com/biotech/markets-thinking-backwards-fdas-1-trial-approval-plan-would-boost-rd-spend-jefferies)**  
  _Dec 5, 2025 10:36am_  
  The FDA’s reported plan to move toward single-trial approvals has stirred industry concern, but one analyst views the proposal as a catalyst for greater R&D investment in the sector.
